Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when VIP crosses your target, drops, or sets a new tracked low—without daily noise.

Price scopeAlert meTarget per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence79 certificate records mentioning this compound or product name36 provider-linked · 66 exact product matches

Status

Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Research area

Immune / inflammation research

This profile is grouped by its dominant research area, not by vendor shelf placement.

Aliases

Vasoactive Intestinal Peptide

Signal depth

Medium

No FDA label signal · 55 trials · 1000 PubMed results

Early

Research evidence

VIP has human trials registered, but none have reported controlled results yet. Most current claims about what it does in people rest on preclinical (lab or animal) work, not published human data.

VIP has 5 name-matched clinical trials (highest phase: Phase 1) and 1000 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet. Note: 8 retracted publications in the literature.

⚠ 8 retracted publications

Human data

Phase 1

Trial quality

Randomized

Outcomes

Surrogate / early

Replication

Meta-analysis

Literature

Top-tier journals

PHASE1Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis TrialVasoactive Intestinal Peptide in COPD NA · RandomizedThe Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine Patients PubMed · 724 citationsInternational Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.Nature · 615 citationsNeuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide The Journal of Immunology · 572 citationsDifferential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from Peyer's patches, mesenteric lymph nodes, and spleen.

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What VIP is

VIP stands for vasoactive intestinal peptide, a signaling peptide that shows up in immune, inflammatory, and neuroregulatory discussions.

Why it matters

It broadens the immune category beyond simple host-defense framing and reflects the fact that some peptide interest is really about signaling networks rather than bodybuilding or cosmetic use.

Regulatory context

VIP is not an FDA-approved general wellness peptide in the United States. It is best treated as an investigational or research-context entry.

Practical reading note

The more complex the signaling story around a peptide, the more important it is to avoid collapsing it into simple consumer promises.